Anchor Therapeutics anchortx.com


Anchor Therapeutics is developing first-in-class pepducin drug candidates, novel molecules that can selectively target G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling.

Anchor Therapeutics is developing first-in-class pepducin drug candidates, novel molecules that can selectively target G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling.

Company (Alive / Active)

Phone: 508-545-2590

Fax:

67 Rogers Street
Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Anchor Therapeutics $10M Aug 18, 2010

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Anchor Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
HealthCare VenturesVenture CapitalCambridge, Massachusetts, United StatesSeries B
Novartis Venture FundsCorporate VentureBasel, SwitzerlandSeries B
TVM CapitalVenture CapitalMunich, GermanySeries B
See all 3 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Cxcr4 receptor compounds Feb 25, 2011 Oct 13, 2015 Patent
Cxcr4 receptor compounds Nov 04, 2009 Aug 04, 2015 Patent
Apj receptor compounds Jul 18, 2014 Application
Apj receptor compounds Jan 09, 2013 Application